Medtronic
Carpediem Cardio-Renal Pediatric Dialysis Emergency Machine, First and Only Pediatric and Neonatal Acute Dialysis Machine in the U.S. for Patients Weighing Between 2.5 and...
The system is indicated for use in acute kidney injury or fluid overloaded patients requiring hemodialysis or hemofiltration therapy. It is intended to provide continuous renal replacement therapy to patients weighing between 2.5 and 10 kilograms.
Medtronic Cryoablation is a Superior Treatment Option for Symptomatic Paroxysmal Atrial Fibrillation Compared to Drug Therapy: Published in New England Journal of Medicine
"The clinical results of STOP AF First demonstrate the superiority of Medtronic cryoablation as a first-line treatment for AF patients, before the disease progresses," said Dr. Oussama Wazni, principal investigator for the STOP AF First trial and section head of electrophysiology at the Cleveland Clinic.
Medtronic Ranked as a Leading Sustainability Company
"Medtronic has never been more focused on our purpose or clearer on our role as a responsible corporate citizen," said Medtronic CEO Geoff Martha. "As stewards of human health and well-being, and with an aspiration to be the undisputed leader in healthcare technology, we are committed to prioritizing sustainability to create a better world. We will continue to invest in the environmental, social, and corporate governance (ESG) efforts that are most aligned to our Mission, while also driving long term growth and profitability."
In-Pen with Real-Time Connect CGM Data: 1st Integrated Smart Insulin Pen for People with Diabetes on Multiple Daily Injections
InPen is the first and only FDA-cleared smart insulin pen on the market for people on multiple daily insulin injections.
Abre Venous Self-Expanding Stent System Receives FDA Approval Reports Medtronic
The device is indicated for use in the iliofemoral veins in patients with symptomatic iliofemoral venous outflow obstruction, also known as deep venous obstruction.
DTM Spinal Cord Stimulation 12 Month Study Results Reported by Medtronic
At 12 months, 84% of patients with chronic back pain treated with DTM Spinal Cord Stimulation reported at least 50% pain relief, compared to 51% of patients treated with conventional SCS (p=0.0005).
First Patient Implanted in ELITE Study of InterStim Micro System
The Evaluation of InterStim Micro System Performance and Safety (ELITE) study will enroll 160 subjects across 40 sites in the United States (and territories), Europe, Australia and Canada. Endpoints include patient-reported outcomes, disease-specific quality of life questionnaires, and symptom diaries. Patients will be followed for two years.
Resolute Onyx Drug Eluting Stent Receives FDA Approval for New 1 Month DAPT Labeling With Expanded Indication for HBR Patients Implanted with the Resolute...
Clinical studies have demonstrated that Resolute Onyx DES and its biocompatible polymer and stent design promote fast vessel healing and is well-suited for patients who may benefit from a DAPT duration as short as one month.
Medtronic Receives Breakthrough Device Designation from FDA
The study begins on the heels of a recent Breakthrough Device Designation issued by the FDA for the Intrepid TTVR System. The Intrepid TTVR system is an investigational device worldwide.
